Clinical Trials | June 15, 2024
Sun Pharma and Moebius Medical present Phase 2b study on MM-II
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Subscribe To Our Newsletter & Stay Updated
